Answers are grounded in this paper and cite their sources.
Monoclonal antibodies are widely used in the treatment of neoplasms and autoimmune diseases. However, it can readily cause hepatotoxicity, with an incidence of 16% among patients using immune checkpoint inhibitors, and it cannot be accurately predicted or avoided. Currently, reviews on liver injury induced by multiple monoclonal antibodies remain lacking. This article provides a review of the clinical characteristics, risk factors, underlying mechanisms, and treatment approaches associated with hepatotoxicity caused by various monoclonal antibodies, including anti-IL-6, anti-TNF-α, anti-HER2, anti-VEGF, and immune checkpoint inhibitors. Aims to provide reference for the safe clinical application of monoclonal antibodies. In this article, liver injury caused by different antibodys has diverse manifestations. Mild cases manifest as transaminases increased, while severe cases can lead to serious consequences such as hepatitis virus reactivation and acute hepatic failure. Risk factors include genetic background (such as HLA genotype), combined medication, underlying hepatic disease, host gender and physical condition. The hepatotoxicity mechanism mainly involves immune-mediated hepatocellular injury, antibody structure-related toxicity, and the cytotoxic payload effect of antibody-drug conjugates (ADCs). Currently, treatment is mainly based on drug withdrawal, hepatoprotective drugs, and Glucocorticoids, and mycophenolate mofetil or other antibodies can be selected for intervention in refractory cases.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: